|

Cobimetinib Clinical Trials

7 actively recruiting trials across 4 locations

Also known as: COTELLIC, Cotellic, GDC 0973, GDC-0973, GDC0973, MEK Inhibitor GDC-0973, RO5514041, XL 518, XL-518, XL518

Other2 trials

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Phase 2/3
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Duarte, California2 trials

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

City of Hope Comprehensive Cancer Center

Phase 2
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

City of Hope Medical Center

Phase 2

Phoenix, Arizona1 trial

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Phoenix Children's Hospital

Phase 2

Atlanta, Georgia1 trial

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Emory University Hospital/Winship Cancer Institute

Phase 1

Portland, Oregon1 trial

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

OHSU Knight Cancer Institute

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.